NL8105449A - Farmaceutische preparaten, die 1-(2,3'-carboxypropionyloxyethyl)-2-methyl-5-nitroimidazol als actief bestanddeel bevatten als geneesmiddel tegen door anaerobe microoerganismen veroorzaakte ziekten. - Google Patents

Farmaceutische preparaten, die 1-(2,3'-carboxypropionyloxyethyl)-2-methyl-5-nitroimidazol als actief bestanddeel bevatten als geneesmiddel tegen door anaerobe microoerganismen veroorzaakte ziekten. Download PDF

Info

Publication number: NL8105449A
Authority: NL; Netherlands
Prior art keywords: compound; methyl; administered; carboxypropionyloxyethyl; anaerobic microorganisms
Prior art date: 1980-12-03

Application number

NL8105449A

Other languages

English (en)

Dutch (nl)

Original Assignee

Silanes Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-12-03

Filing date

1981-12-02

Publication date

1982-07-01

1981-12-02 Application filed by Silanes Lab filed Critical Silanes Lab

1982-07-01 Publication of NL8105449A publication Critical patent/NL8105449A/nl

Links

244000005700 microbiome Species 0.000 title claims description 6
201000010099 disease Diseases 0.000 title claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
239000000825 pharmaceutical preparation Substances 0.000 title description 4
239000013543 active substance Substances 0.000 title 1
239000000203 mixture Substances 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 14
238000000034 method Methods 0.000 claims description 11
-1 aliphatic amino acids Chemical class 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
FFYTTYVSDVWNMY-UHFFFAOYSA-N 2-Methyl-5-nitroimidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1 FFYTTYVSDVWNMY-UHFFFAOYSA-N 0.000 claims description 3
241000193468 Clostridium perfringens Species 0.000 claims description 3
241000191992 Peptostreptococcus Species 0.000 claims description 3
150000001342 alkaline earth metals Chemical class 0.000 claims description 3
238000011200 topical administration Methods 0.000 claims description 3
241000193403 Clostridium Species 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
238000009472 formulation Methods 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
239000002585 base Substances 0.000 claims 4
150000007513 acids Chemical class 0.000 claims 3
229910021529 ammonia Inorganic materials 0.000 claims 2
241000606124 Bacteroides fragilis Species 0.000 claims 1
241000193464 Clostridium sp. Species 0.000 claims 1
241001135223 Prevotella melaninogenica Species 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
239000003513 alkali Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000000654 additive Substances 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024652 Liver abscess Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000463 material Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
206010038351 renal abscess Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
239000000003 vaginal tablet Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL8105449A 1980-12-03 1981-12-02 Farmaceutische preparaten, die 1-(2,3'-carboxypropionyloxyethyl)-2-methyl-5-nitroimidazol als actief bestanddeel bevatten als geneesmiddel tegen door anaerobe microoerganismen veroorzaakte ziekten. NL8105449A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
MX809191U MX6789E (es)	1980-12-03	1980-12-03	Procedimiento para la elaboracion de composiciones antibacterianas a base de 1-(2,3'-carboxipropioniloxietil)-2-metil-5-nitroimidazol
MX919180		1980-12-03

Publications (1)

Publication Number	Publication Date
NL8105449A true NL8105449A (nl)	1982-07-01

Family

ID=19741552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8105449A NL8105449A (nl)	1980-12-03	1981-12-02	Farmaceutische preparaten, die 1-(2,3'-carboxypropionyloxyethyl)-2-methyl-5-nitroimidazol als actief bestanddeel bevatten als geneesmiddel tegen door anaerobe microoerganismen veroorzaakte ziekten.

Country Status (12)

Country	Link
JP (1)	JPS57188518A (de)
BE (1)	BE891284A (de)
CA (1)	CA1184120A (de)
CH (1)	CH652597A5 (de)
DE (1)	DE3147959A1 (de)
FR (1)	FR2494993A1 (de)
GB (1)	GB2089208A (de)
IT (1)	IT1145989B (de)
LU (1)	LU83802A1 (de)
MX (1)	MX6789E (de)
NL (1)	NL8105449A (de)
PT (1)	PT74056B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1194283B (it) *	1983-06-21	1988-09-14	Isnardi Pietro & C Spa	Derivato idrosolubile del 1-(2-idrossietil)-2-metil-5-nitro-imidazolo ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IL100323A0 (en) *	1990-12-11	1992-09-06	Brocades Pharma Bv	Heterocyclic carboxylic esters,their preparation and their use for the preparation of gastro-intestinal medicines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB983123A (en) *	1961-07-07	1965-02-10	Rhone Poulenc Sa	Improvements in or relating to imidazole derivatives

1980
- 1980-12-03 MX MX809191U patent/MX6789E/es unknown
1981
- 1981-11-27 IT IT12688/81A patent/IT1145989B/it active
- 1981-11-27 PT PT74056A patent/PT74056B/pt unknown
- 1981-11-30 BE BE//206684A patent/BE891284A/fr not_active IP Right Cessation
- 1981-12-01 CH CH7680/81A patent/CH652597A5/de not_active IP Right Cessation
- 1981-12-01 LU LU83802A patent/LU83802A1/fr unknown
- 1981-12-02 NL NL8105449A patent/NL8105449A/nl not_active Application Discontinuation
- 1981-12-02 FR FR8122594A patent/FR2494993A1/fr active Pending
- 1981-12-02 GB GB8136309A patent/GB2089208A/en not_active Withdrawn
- 1981-12-03 CA CA000391456A patent/CA1184120A/en not_active Expired
- 1981-12-03 JP JP56193768A patent/JPS57188518A/ja active Pending
- 1981-12-03 DE DE19813147959 patent/DE3147959A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
LU83802A1 (fr)	1983-09-01
MX6789E (es)	1986-07-21
IT8112688A0 (it)	1981-11-27
JPS57188518A (en)	1982-11-19
CH652597A5 (de)	1985-11-29
CA1184120A (en)	1985-03-19
PT74056A (en)	1981-12-01
IT1145989B (it)	1986-11-12
FR2494993A1 (fr)	1982-06-04
PT74056B (en)	1983-04-26
GB2089208A (en)	1982-06-23
DE3147959A1 (de)	1983-03-24
BE891284A (fr)	1982-06-01

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1985-08-01	BV	The patent application has lapsed

Publication	Publication Date	Title
DE69126701T2 (de)	1997-12-04	Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
TW201936596A (zh)	2019-09-16	Ｔｌｒ７／８拮抗劑及其用途
US11833148B2 (en)	2023-12-05	Methods for treating or limiting development of cardiovascular disease-related neurological disorders
JPS59144779A (ja)	1984-08-18	（＋）カテキン塩
KR19980703805A (ko)	1998-12-05	포유동물내 암 및 바이러스 성장 억제용, 엔-클로로페닐카르바메이트, 엔-클로로페닐티오카르바메이트 및 엔-포스포노글리신 유도체 함유 약학 조성물
JPH09501653A (ja)	1997-02-18	薬学的組成物
MXPA96004483A (en)	1998-02-01	Derivatives of benzamide, compositions that contain such derivative and use of the mis
KR100348440B1 (ko)	2002-11-29	벤즈아미드유도체,그유도체로구성된조성물및그의용도
US3655897A (en)	1972-04-11	Anti-inflammatory agents
JPH10158169A (ja)	1998-06-16	塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
DE69516110T2 (de)	2000-09-28	Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
NL8105449A (nl)	1982-07-01	Farmaceutische preparaten, die 1-(2,3'-carboxypropionyloxyethyl)-2-methyl-5-nitroimidazol als actief bestanddeel bevatten als geneesmiddel tegen door anaerobe microoerganismen veroorzaakte ziekten.
EP0070084A2 (de)	1983-01-19	Imidazolin-Derivate
CA3231945A1 (en)	2023-03-23	Thiostrepton compositions and preparation thereof
KR20070026187A (ko)	2007-03-08	2개 이상의 활성 물질을 함유하는 주사용 멸균 약제학적제형
WO2002074311A1 (en)	2002-09-26	Antitumoral, antiviral, antibacterial, antiparasitic, anti-inflammatory, immunomodulatory and antimicotic medicinal preparation, method for production and dosage forms thereof
JPS63258415A (ja)	1988-10-25	Ｎ−置換２−シアンアジリジンを含有する免疫刺戟性薬剤
NL8101987A (nl)	1981-11-16	De verbinding 4-amino-1-beta-d-ribofuranosyl-1h-imidazo/4.5-c/-pyridine of een farmaceutisch aanvaardbaar zuuradditiezout daarvan; farmaceutisch preparaat.
US2791531A (en)	1957-05-07	Erythromycin thiocyanate and compositions containing same
EP0442744A2 (de)	1991-08-21	Behandlung viraler Erkrankungen mit Glykosiden
EP0086774A1 (de)	1983-08-31	Behandlung von kozzidieninfektionen mittels amidinoharnstoff- oder amidinothioharnstoffabkömmlingen
SK695188A3 (en)	1996-02-07	Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n-(2- -pyridyl)-2h-thieno (2,3-e)-1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent
NL8203983A (nl)	1983-05-16	Fosforamide derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze bevatten.
US7704976B2 (en)	2010-04-27	Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention
SU1547251A1 (ru)	1991-04-07	2-Окси-3,5-дийод-N-[2-(4-галогеннафтокси-1)-5-хлорфенил]-бензамиды, обладающие противомал рийной активностью